These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36274045)

  • 41. Effect of Lumacaftor/Ivacaftor on Pulmonary Exacerbation Rates in Members with Cystic Fibrosis in a Medicaid Population.
    Tesell MA; Alper CJ; Bacon R; Greenwood BC; Lenz K; Jeffrey PL; Stevens K
    J Manag Care Spec Pharm; 2019 Sep; 25(9):1021-1025. PubMed ID: 31456498
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Changes in LCI in F508del/F508del patients treated with lumacaftor/ivacaftor: Results from the prospect study.
    Shaw M; Khan U; Clancy JP; Donaldson SH; Sagel SD; Rowe SM; Ratjen F;
    J Cyst Fibros; 2020 Nov; 19(6):931-933. PubMed ID: 32513528
    [TBL] [Abstract][Full Text] [Related]  

  • 43. AJRCCM: 100-Year Anniversary. Progress along the Pathway of Discovery Leading to Treatment and Cure of Cystic Fibrosis.
    Ramsey BW; Welsh MJ
    Am J Respir Crit Care Med; 2017 May; 195(9):1092-1099. PubMed ID: 28459323
    [No Abstract]   [Full Text] [Related]  

  • 44. Profiling the response to lumacaftor-ivacaftor in children with cystic between fibrosis and new insight from a French-Italian real-life cohort.
    Cornet M; Robin G; Ciciriello F; Bihouee T; Marguet C; Roy V; Lebourgeois M; Chedevergne F; Bonnel AS; Kelly M; Reix P; Lucidi V; Stoven V; Sermet-Gaudelus I
    Pediatr Pulmonol; 2022 Dec; 57(12):2992-2999. PubMed ID: 35996214
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lumacaftor-ivacaftor (Orkambi) for cystic fibrosis: behind the 'breakthrough'.
    Mayer M
    Evid Based Med; 2016 Jun; 21(3):83-6. PubMed ID: 26718821
    [No Abstract]   [Full Text] [Related]  

  • 46. Elexacaftor/tezacaftor/ivacaftor (Trikafta) for cystic fibrosis.
    Med Lett Drugs Ther; 2020 Jan; 62(1589):5-7. PubMed ID: 31999662
    [No Abstract]   [Full Text] [Related]  

  • 47. Emerging preclinical modulators developed for F508del-CFTR have the potential to be effective for ORKAMBI resistant processing mutants.
    Laselva O; Bartlett C; Popa A; Ouyang H; Gunawardena TNA; Gonska T; Moraes TJ; Bear CE
    J Cyst Fibros; 2021 Jan; 20(1):106-119. PubMed ID: 32741662
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Cystic Fibrosis: toward a genetic treatment; Clostridium difficile versus Clostridium difficile].
    Nau JY
    Rev Med Suisse; 2015 May; 11(476):1210-1. PubMed ID: 26182641
    [No Abstract]   [Full Text] [Related]  

  • 49. Radiomics-derived morphological features predict pulmonary function response during lumacaftor/ivacaftor therapy in patients with cystic fibrosis.
    Zhang B; Zhang S
    Eur Respir J; 2022 Jul; 60(1):. PubMed ID: 35086826
    [No Abstract]   [Full Text] [Related]  

  • 50. A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for
    Rayment JH; Asfour F; Rosenfeld M; Higgins M; Liu L; Mascia M; Paz-Diaz H; Tian S; Zahigian R; McColley SA
    Am J Respir Crit Care Med; 2022 Nov; 206(10):1239-1247. PubMed ID: 35771568
    [No Abstract]   [Full Text] [Related]  

  • 51. VO
    Wilson J; You X; Ellis M; Urquhart DS; Jha L; Duncan M; Tian S; Harris RA; Kotsimbos T; Keating D
    J Cyst Fibros; 2021 May; 20(3):499-505. PubMed ID: 33358691
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lumacaftor/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR.
    Milla CE; Ratjen F; Marigowda G; Liu F; Waltz D; Rosenfeld M;
    Am J Respir Crit Care Med; 2017 Apr; 195(7):912-920. PubMed ID: 27805836
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients.
    Kutney K; Donnola SB; Flask CA; Gubitosi-Klug R; O'Riordan M; McBennett K; Sferra TJ; Kaminski B
    World J Hepatol; 2019 Dec; 11(12):761-772. PubMed ID: 31966908
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study.
    McNamara JJ; McColley SA; Marigowda G; Liu F; Tian S; Owen CA; Stiles D; Li C; Waltz D; Wang LT; Sawicki GS
    Lancet Respir Med; 2019 Apr; 7(4):325-335. PubMed ID: 30686767
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.
    Chilvers MA; Davies JC; Milla C; Tian S; Han Z; Cornell AG; Owen CA; Ratjen F
    Lancet Respir Med; 2021 Jul; 9(7):721-732. PubMed ID: 33516285
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study.
    Hoppe JE; Chilvers M; Ratjen F; McNamara JJ; Owen CA; Tian S; Zahigian R; Cornell AG; McColley SA
    Lancet Respir Med; 2021 Sep; 9(9):977-988. PubMed ID: 33965000
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.
    Boyle MP; Bell SC; Konstan MW; McColley SA; Rowe SM; Rietschel E; Huang X; Waltz D; Patel NR; Rodman D;
    Lancet Respir Med; 2014 Jul; 2(7):527-38. PubMed ID: 24973281
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis.
    Talamo Guevara M; McColley SA
    Expert Opin Drug Saf; 2017 Nov; 16(11):1305-1311. PubMed ID: 28846049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.